Last reviewed · How we verify
3% Benzoyl Peroxide
3% Benzoyl Peroxide, marketed by GlaxoSmithKline, is an established topical acne treatment with a strong presence in the dermatological market. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity and potential revenue protection. However, the primary risk lies in the potential for increased competition once the patent expires, which could erode market share and revenue.
At a glance
| Generic name | 3% Benzoyl Peroxide |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- Positive Assurance and mTBI (NA)
- Functional Instability in Patients Suffering From Collagen Disease and Joint Hypermobility
- An Observational Clinical Study to Evaluate the Efficacy of the CeraVe Skin Care Line
- Benzydamine Hydrochloride and Post-operative Sore Throat (EARLY_PHASE1)
- The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment (PHASE2)
- An Investigation of a Multi-Function Skincare Product to Improve Aging, Eczema, and Acne Outcomes (NA)
- European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 3% Benzoyl Peroxide CI brief — competitive landscape report
- 3% Benzoyl Peroxide updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI